Get started
Author

Deyaa Rafaat Adib

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
2020 · Franck Morschhauser, Hervé Tilly, et al. · The Lancet Oncology · 610
Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
2019 · Franck Morschhauser, Herve Tilly, et al. · Blood · 37
Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2018 · Vincent Ribrag, Franck Morschhauser, et al. · Blood · 27
Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma
2019 · F. Morschhauser, H. Tilly, et al. · Hematological Oncology · 15
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
2022 · David Proudman, Dave Nellesen, et al. · Advances in Therapy · 10
PDF
First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors.
2015 · Devalingam Mahalingam, Manish R. Patel, et al. · Journal of Clinical Oncology · 9
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
2023 · Benjamin L. Schlechter, Daniel Olson, et al. · Journal of Clinical Oncology · 7
Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
2021 · Connie Lee Batlevi, Steven I. Park, et al. · Blood · 5
Development of a phase Ib/IIa proof-of-concept study of imalumab (BAX69), a first-in-class anti-macrophage migration inhibitory factor (MIF) antibody, as the 3rd or 4th line treatment in metastatic colorectal cancer (mCRC).
2015 · Xiaochun Liu, Deyaa Rafaat Adib, et al. · Journal of Clinical Oncology · 5
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
2024 · Benjamin L. Schlechter, Ecaterina Elena Dumbrava, et al. · Journal of Clinical Oncology · 3
PDF
586P Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
2021 · W. Abida, N. Iannotti, et al. · Annals of Oncology · 3
Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response
2020 · Gilles Salles, Hervé Tilly, et al. · Blood · 3
A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2020 · Wassim Abida, Thomas Paul Bradley, et al. · Journal of Clinical Oncology · 3
Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.
2025 · Vincent J. Picozzi, Anna M. Varghese, et al. · Journal of Clinical Oncology · 2
PDF
654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
2023 · Daniel J Olson, Ecaterina Dumbrava, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors
2023 · Daniel J Olson, Ecaterina Dumbrava, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Abstract CT234: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
2023 · Ecaterina Elena Dumbrava, Daniel Olson, et al. · Cancer Research · 1
Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat
2021 · Sandeep S. Dave, Lanie Happ, et al. · Blood · 1
Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials
2020 · David Proudman, Dave Nellesen, et al. · Blood · 1
IBCL-178: A Phase 1b/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
2020 · John Leonard, Connie Lee Batlevi, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
The OMNI Patient Registry: A Prospective, Observational, Non-Interventional Registry to Evaluate Vascular Safety of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
2017 · Annette Stemhagen, Deyaa Adib, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Abstract CT081: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors
2024 · Ecaterina E. Dumbrava, Daniel Olson, et al. · Cancer Research
First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.
2024 · Ecaterina Elena Dumbrava, Davendra Sohal, et al. · Journal of Clinical Oncology
Abstract C028: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors
2023 · Benjamin Schlechter, Ecaterina Dumbrava, et al. · Molecular Cancer Therapeutics
Abstract B035: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
2023 · Benjamin Schlechter, Ecaterina Dumbrava, et al. · Molecular Cancer Therapeutics
Works count: 33
Citation count: 746
H-index: 7
I10-index: 5
Year
Topic
Type